At a meeting held in Mumbai today, the Board of Novartis India Limited approved results for the quarter ended 30 June 2015. During the period under review, Total Income from Operations was Rs 224.1 crore as compared to Rs 208.8 crore during the corresponding quarter of the previous year.
During the quarter under review, our core business, Pharmaceuticals recorded Total Income from Operations of Rs 168.9 crore as against Rs 150.6 crore in the previous corresponding quarter. The Generics business registered Total Income from Operations of Rs 11.2 crore as against Rs 12.3 crore in the previous corresponding period. The Animal Health business registered Total Income from Operations of Rs 24.5 crore as against Rs 23.0 crore in the previous corresponding period. The OTC business recorded Total Income from Operations of Rs 19.5 crore as against Rs 22.8 crore in the previous corresponding quarter.
During the quarter under review the Company recorded a Profit from Operations of Rs 0.4 crore as compared to Loss from Operations of Rs 4.0 crore during the corresponding quarter of the previous year. The Company registered Net Profit after Other Income of Rs 13.5 crore as against Rs 14.3 crore in the previous corresponding period.
Issued by Corporate Communications on 22 July 2015
Media contacts
Svetlana Pinto
+91-22-24951074 (direct)
+91-98210 54884 (mobile)
Email: [email protected]